• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

数学建模揭示了嵌合抗原受体T细胞(CAR-T)疗法和巨噬细胞介导的细胞因子释放综合征的时间线。

Mathematical modeling unveils the timeline of CAR-T cell therapy and macrophage-mediated cytokine release syndrome.

作者信息

Santurio Daniela S, Barros Luciana R C, Glauche Ingmar, Fassoni Artur C

机构信息

Certara UK Ltd., Sheffield, United Kingdom.

Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.

出版信息

PLoS Comput Biol. 2025 Apr 9;21(4):e1012908. doi: 10.1371/journal.pcbi.1012908. eCollection 2025 Apr.

DOI:10.1371/journal.pcbi.1012908
PMID:40203243
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11981663/
Abstract

Chimeric antigen receptor (CAR)-T cell therapy holds significant potential for cancer treatment, although disease relapse and cytokine release syndrome (CRS) remain as frequent clinical challenges. To better understand the mechanisms underlying the temporal dynamics of CAR-T cell therapy response and CRS, we developed a novel multi-layer mathematical model incorporating antigen-mediated CAR-T cell expansion, antigen-negative resistance, and macrophage-associated cytokine release. Three key mechanisms of macrophage activation are considered: release of damage-associated molecular patterns, antigen-binding mediated activation, and CD40-CD40L contact. The model accurately describes 25 patient time courses with different responses and IL-6 cytokine kinetics. We successfully link the dynamic shape of the response to interpretable model parameters and investigate the influence of CAR-T cell dose and initial tumor burden on the occurrence of cytokine release and treatment outcome. By disentangling the timeline of macrophage activation, the model identified distinct contributions of each activation mechanism, suggesting the CD40-CD40L axis as a major driver of cytokine release and a clinically feasible target to control the activation process and modulate cytokine peak height. Our multi-layer model provides a comprehensive framework for understanding the complex interactions between CAR-T cells, tumor cells, and macrophages during therapy.

摘要

嵌合抗原受体(CAR)-T细胞疗法在癌症治疗方面具有巨大潜力,尽管疾病复发和细胞因子释放综合征(CRS)仍然是常见的临床挑战。为了更好地理解CAR-T细胞疗法反应和CRS时间动态背后的机制,我们开发了一种新型的多层数学模型,该模型纳入了抗原介导的CAR-T细胞扩增、抗原阴性抗性和巨噬细胞相关的细胞因子释放。考虑了巨噬细胞激活的三个关键机制:损伤相关分子模式的释放、抗原结合介导的激活以及CD40-CD40L接触。该模型准确描述了25例具有不同反应和IL-6细胞因子动力学的患者时间进程。我们成功地将反应的动态形状与可解释的模型参数联系起来,并研究了CAR-T细胞剂量和初始肿瘤负荷对细胞因子释放发生和治疗结果的影响。通过梳理巨噬细胞激活的时间线,该模型确定了每种激活机制的不同贡献,表明CD40-CD40L轴是细胞因子释放的主要驱动因素,也是控制激活过程和调节细胞因子峰值高度的临床可行靶点。我们的多层模型为理解治疗期间CAR-T细胞、肿瘤细胞和巨噬细胞之间的复杂相互作用提供了一个全面的框架。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7468/11981663/5291dfa54ff5/pcbi.1012908.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7468/11981663/d0530b50c379/pcbi.1012908.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7468/11981663/005ce940b674/pcbi.1012908.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7468/11981663/2be8b744e766/pcbi.1012908.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7468/11981663/6eaf42ec4226/pcbi.1012908.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7468/11981663/8d260f422f16/pcbi.1012908.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7468/11981663/00fd533d6076/pcbi.1012908.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7468/11981663/3bc4dcb38073/pcbi.1012908.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7468/11981663/5291dfa54ff5/pcbi.1012908.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7468/11981663/d0530b50c379/pcbi.1012908.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7468/11981663/005ce940b674/pcbi.1012908.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7468/11981663/2be8b744e766/pcbi.1012908.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7468/11981663/6eaf42ec4226/pcbi.1012908.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7468/11981663/8d260f422f16/pcbi.1012908.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7468/11981663/00fd533d6076/pcbi.1012908.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7468/11981663/3bc4dcb38073/pcbi.1012908.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7468/11981663/5291dfa54ff5/pcbi.1012908.g008.jpg

相似文献

1
Mathematical modeling unveils the timeline of CAR-T cell therapy and macrophage-mediated cytokine release syndrome.数学建模揭示了嵌合抗原受体T细胞(CAR-T)疗法和巨噬细胞介导的细胞因子释放综合征的时间线。
PLoS Comput Biol. 2025 Apr 9;21(4):e1012908. doi: 10.1371/journal.pcbi.1012908. eCollection 2025 Apr.
2
In-depth analysis of the safety of CAR-T cell therapy for solid tumors.嵌合抗原受体T细胞(CAR-T)疗法治疗实体瘤安全性的深入分析。
Front Immunol. 2025 Feb 24;16:1548979. doi: 10.3389/fimmu.2025.1548979. eCollection 2025.
3
Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.嵌合抗原受体 T 细胞治疗中细胞因子释放综合征的特征和危险因素。
Front Immunol. 2021 Feb 23;12:611366. doi: 10.3389/fimmu.2021.611366. eCollection 2021.
4
CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead.嵌合抗原受体 T 细胞疗法在癌症治疗中的困境与展望
J Immunol Res. 2020 Jan 17;2020:1924379. doi: 10.1155/2020/1924379. eCollection 2020.
5
CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response.CD40 配体修饰的嵌合抗原受体 T 细胞通过引发内源性抗肿瘤反应增强抗肿瘤功能。
Cancer Cell. 2019 Mar 18;35(3):473-488.e6. doi: 10.1016/j.ccell.2019.02.006.
6
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy.乘风破浪:CAR-T 细胞疗法中细胞因子相关毒性的管理。
Semin Immunopathol. 2024 Jul 16;46(3-4):5. doi: 10.1007/s00281-024-01013-w.
7
Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated immunosuppression induced by CAR-T treatment.阻断 AIM2 炎性体或 α1-AR 可减轻 CAR-T 治疗引起的 IL-1β 释放和巨噬细胞介导的免疫抑制。
J Immunother Cancer. 2021 Jan;9(1). doi: 10.1136/jitc-2020-001466.
8
[Establishment of a cytokine release syndrome associated with chimeric antigen receptor T cell treatment in SCID/Beige mice model].[在SCID/米色小鼠模型中建立与嵌合抗原受体T细胞治疗相关的细胞因子释放综合征]
Zhonghua Zhong Liu Za Zhi. 2021 Dec 23;43(12):1248-1254. doi: 10.3760/cma.j.cn112152-20190916-00598.
9
Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model.利用多尺度系统 PK-PD 模型建立 CAR 亲和力、抗原丰度、肿瘤细胞耗竭和 CAR-T 细胞扩增之间的定量关系。
MAbs. 2020 Jan-Dec;12(1):1688616. doi: 10.1080/19420862.2019.1688616.
10
Novel strategies to assess cytokine release mediated by chimeric antigen receptor T cells based on the adverse outcome pathway concept.基于不良结局途径概念评估嵌合抗原受体T细胞介导的细胞因子释放的新策略。
J Immunotoxicol. 2024 Oct;21(sup1):S13-S28. doi: 10.1080/1547691X.2024.2345158. Epub 2024 Dec 10.

引用本文的文献

1
Cytokine release syndrome and CAR T Cell therapy: Modulating the intensity of the inflammatory response and resolution within the tumor microenvironment.细胞因子释放综合征与嵌合抗原受体T细胞疗法:调节肿瘤微环境中炎症反应的强度及消退
Front Pharmacol. 2025 Jun 10;16:1615526. doi: 10.3389/fphar.2025.1615526. eCollection 2025.

本文引用的文献

1
Systemic toxicity of CAR-T therapy and potential monitoring indicators for toxicity prevention.嵌合抗原受体 T 细胞疗法的全身毒性及潜在毒性监测指标。
Front Immunol. 2024 Aug 26;15:1422591. doi: 10.3389/fimmu.2024.1422591. eCollection 2024.
2
Cell-Based Models of 'Cytokine Release Syndrome' Endorse CD40L and Granulocyte-Macrophage Colony-Stimulating Factor Knockout in Chimeric Antigen Receptor T Cells as Mitigation Strategy.基于细胞的“细胞因子释放综合征”模型支持嵌合抗原受体 T 细胞中 CD40L 和粒细胞-巨噬细胞集落刺激因子敲除作为缓解策略。
Cells. 2023 Nov 6;12(21):2581. doi: 10.3390/cells12212581.
3
The total mass, number, and distribution of immune cells in the human body.
人体中免疫细胞的总质量、数量和分布。
Proc Natl Acad Sci U S A. 2023 Oct 31;120(44):e2308511120. doi: 10.1073/pnas.2308511120. Epub 2023 Oct 23.
4
QSP Designer: Quantitative systems pharmacology modeling with modular biological process map notation and multiple language code generation.QSP Designer:基于模块化生物过程图谱符号和多种语言代码生成的定量系统药理学建模。
CPT Pharmacometrics Syst Pharmacol. 2023 Jul;12(7):889-903. doi: 10.1002/psp4.12972. Epub 2023 May 4.
5
Data driven model discovery and interpretation for CAR T-cell killing using sparse identification and latent variables.使用稀疏识别和潜在变量进行 CAR T 细胞杀伤的数据驱动模型发现和解释。
Front Immunol. 2023 May 15;14:1115536. doi: 10.3389/fimmu.2023.1115536. eCollection 2023.
6
Deconvolution of clinical variance in CAR-T cell pharmacology and response.脱卷积 CAR-T 细胞药代动力学和反应中的临床变异性。
Nat Biotechnol. 2023 Nov;41(11):1606-1617. doi: 10.1038/s41587-023-01687-x. Epub 2023 Feb 27.
7
Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse.嵌合抗原受体 T 细胞免疫疗法的计算模型可解析并预测缓解、耐药和复发时白血病患者的反应。
J Immunother Cancer. 2022 Dec;10(12). doi: 10.1136/jitc-2022-005360.
8
A Computational Model of Cytokine Release Syndrome during CAR T-cell Therapy.嵌合抗原受体T细胞疗法期间细胞因子释放综合征的计算模型。
Adv Ther (Weinh). 2022 Oct;5(10). doi: 10.1002/adtp.202200130. Epub 2022 Aug 4.
9
Dose-response correlation for CAR-T cells: a systematic review of clinical studies.CAR-T 细胞的剂量反应相关性:临床研究的系统评价。
J Immunother Cancer. 2022 Dec;10(12). doi: 10.1136/jitc-2022-005678.
10
Modeling Patient-Specific CAR-T Cell Dynamics: Multiphasic Kinetics via Phenotypic Differentiation.模拟患者特异性嵌合抗原受体T细胞动力学:通过表型分化的多相动力学
Cancers (Basel). 2022 Nov 14;14(22):5576. doi: 10.3390/cancers14225576.